Cartesian Therapeutics Inc (RNAC)
19.12
-0.56
(-2.85%)
USD |
NASDAQ |
Nov 04, 16:00
19.12
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Enterprise Value: 369.67M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 369.67M |
| November 01, 2024 | 383.06M |
| October 31, 2024 | 385.92M |
| October 30, 2024 | 417.94M |
| October 29, 2024 | 446.86M |
| October 28, 2024 | 445.66M |
| October 25, 2024 | 404.56M |
| October 24, 2024 | 440.89M |
| October 23, 2024 | 442.80M |
| October 22, 2024 | 442.32M |
| October 21, 2024 | 451.64M |
| October 18, 2024 | 459.29M |
| October 17, 2024 | 431.33M |
| October 16, 2024 | 435.63M |
| October 15, 2024 | 405.76M |
| October 14, 2024 | 434.91M |
| October 11, 2024 | 442.32M |
| October 10, 2024 | 412.69M |
| October 09, 2024 | 443.75M |
| October 08, 2024 | 489.16M |
| October 07, 2024 | 455.46M |
| October 04, 2024 | 498.72M |
| October 03, 2024 | 458.09M |
| October 02, 2024 | 342.67M |
| October 01, 2024 | 321.59M |
| Date | Value |
|---|---|
| September 30, 2024 | 297.94M |
| September 27, 2024 | 318.96M |
| September 26, 2024 | 327.56M |
| September 25, 2024 | 305.58M |
| September 24, 2024 | 257.54M |
| September 23, 2024 | 230.81M |
| September 20, 2024 | 255.61M |
| September 19, 2024 | 266.52M |
| September 18, 2024 | 247.06M |
| September 17, 2024 | 268.45M |
| September 16, 2024 | 255.19M |
| September 13, 2024 | 271.01M |
| September 12, 2024 | 256.47M |
| September 11, 2024 | 244.49M |
| September 10, 2024 | 230.59M |
| September 09, 2024 | 193.38M |
| September 06, 2024 | 190.38M |
| September 05, 2024 | 213.05M |
| September 04, 2024 | 200.65M |
| September 03, 2024 | 193.38M |
| August 30, 2024 | 211.27M |
| August 29, 2024 | 231.59M |
| August 28, 2024 | 217.26M |
| August 27, 2024 | 212.98M |
| August 26, 2024 | 212.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-30.00M
Minimum
Apr 05 2024
547.56M
Maximum
Jun 07 2024
189.64M
Average
181.36M
Median
May 04 2020
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 33.06B |
| Amgen Inc | 221.77B |
| Johnson & Johnson | 396.44B |
| Regeneron Pharmaceuticals Inc | 83.27B |
| NovaBay Pharmaceuticals Inc | 3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 13.84M |
| Revenue (Quarterly) | 33.44M |
| Total Expenses (Quarterly) | 19.69M |
| EPS Diluted (Quarterly) | 0.54 |
| Profit Margin (Quarterly) | 41.37% |
| Earnings Yield | -279.6% |
| Normalized Earnings Yield | -99.19 |